CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX
- 1 August 2019
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (8) , 1453-1459
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Radical surgery of oligometastatic pancreatic cancerEuropean Journal of Surgical Oncology, 2017
- Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?European Journal of Surgical Oncology, 2016
- Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysisSurgery, 2016
- Pancreatic cancer: from state-of-the-art treatments to promising novel therapiesNature Reviews Clinical Oncology, 2015
- Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)Surgery, 2014
- Superselective Embolization for the Management of Postpancreatectomy Hemorrhage: A Single-Center Experience in 25 PatientsJournal of Vascular and Interventional Radiology, 2012
- The prognostic and predictive value of serum CA19.9 in pancreatic cancerAnnals of Oncology, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Adenocarcinoma of the pancreas: CT imagingRadiologic Clinics of North America, 2002
- Principles and practical application of the receiver-operating characteristic analysis for diagnostic testsPreventive Veterinary Medicine, 2000